SHAREHOLDERS' EQUITY - Narrative (Details)				12 Months Ended		46 Months Ended
	Nov. 17, 2022 USD ($) $ / shares shares	Feb. 04, 2020 USD ($) sales_agent	Jul. 18, 2011	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2022 USD ($) $ / shares shares	Aug. 31, 2022 USD ($)	Aug. 02, 2022 USD ($)	Aug. 01, 2022 USD ($)	Jul. 28, 2021 USD ($)	May 26, 2021 USD ($)	Mar. 04, 2019 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Right to grant period			10 years
Repurchase authorized amount							$ 20,000,000			$ 20,000,000
Public Equity Offering
Subsidiary or Equity Method Investee [Line Items]
Number of shares sold (in shares) | shares	2,534,436
Par value, common stock (in usd per share) | $ / shares	$ 18.15
Gross proceeds received	$ 46,000,000
Net proceeds received	$ 44,100,000
Equity ATM Program
Subsidiary or Equity Method Investee [Line Items]
Number of shares sold (in shares) | shares				8,435,462	3,872,031	16,613,122
Gross proceeds received				$ 161,216,000	$ 99,636,000	$ 344,700,000
Net proceeds received				$ 158,798,000	$ 98,142,000	$ 339,100,000
Maximum consideration threshold		$ 100,000,000						$ 650,000,000	$ 250,000,000		$ 250,000,000	$ 50,000,000
Number of additional sales agents | sales_agent		2
Gross sales commission percentage											1.50%	2.00%
Weighted average price per share (in usd per share) | $ / shares				$ 19.11	$ 25.73	$ 20.75
Available under the Equity ATM Program				$ 305,300,000
2010 Plan | Restricted Stock
Subsidiary or Equity Method Investee [Line Items]
Right to grant period			10 years